Clinical Trials in Beersheba, Southern District
14 recruiting
Showing 1–14 of 14 trials
Recruiting
Phase 2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Graves Disease
Immunovant Sciences GmbH210 enrolled126 locationsNCT07018323
Recruiting
Phase 1
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
MelanomaNon-small Cell Lung CancerThyroid Cancer+10 more
Pfizer124 enrolled39 locationsNCT05538130
Recruiting
Phase 3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Follicular Lymphoma ( FL)
Genmab1,095 enrolled266 locationsNCT06191744
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled121 locationsNCT06152575
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Bipolar DisorderMania
Bristol-Myers Squibb424 enrolled103 locationsNCT07140913
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
Bipolar Disorder Type I With Mania or Mania With Mixed Features
Bristol-Myers Squibb274 enrolled74 locationsNCT06951711
Recruiting
Phase 3
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Bipolar Disorder Type I With Mania
Bristol-Myers Squibb450 enrolled170 locationsNCT06929273
Recruiting
Phase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
AbbVie698 enrolled316 locationsNCT04928846
Recruiting
Phase 3
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
AbbVie675 enrolled148 locationsNCT06461897
Recruiting
Phase 2
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Crohn's Disease
AbbVie540 enrolled254 locationsNCT06548542
Recruiting
Phase 2
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Esophageal AdenocarcinomaGastroesophageal Junction AdenocarcinomaLocally Advanced Unresectable or Metastatic Gastric Adenocarcinoma
AbbVie180 enrolled49 locationsNCT06628310
Recruiting
Phase 3
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
Ulcerative Colitis
AbbVie530 enrolled270 locationsNCT06880744
Recruiting
Phase 2Phase 3
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Neoplasms
Celgene1,541 enrolled200 locationsNCT03435796
Recruiting
Phase 1Phase 2
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Multiple Myeloma
AbbVie440 enrolled25 locationsNCT06892522